Researchers at Harvard Medical School and the Massachusetts General Hospital in Boston, Massachusetts are developing a new lung cancer drug for Pfizer. Currently in the early phases of a stage 3 clinical trial, Crizotinib was successful in shrinking non-small cell lung cancer tumors by at least 30% in 47 of 82 patients exhibiting cancers with a specific mutation in the anaplastic lymphoma kinase gene. Tumor growth halted in another 27 patients in the study, meaning that 90% of (the admittedly small) test base showed at least some benefit from taking the drug.